Progress in neuro-psychopharmacology & biological psychiatry
April 2, 2025
Simon Reiche, Tim Hirschfeld, Anna Lena Gröticke et al.
5 citations
Evidence on the neuropsychological consequences of classic psychedelics like psilocybin, LSD, and ayahuasca is conflicting, and little is known about how sporadic use of psychedelics under naturalistic conditions may affect cognitive functioning. Given the growing interest in the therapeutic potential of psychedelics and the rise in non-medical use, further exploration into their...
Scientific Reports
December 31, 2024
Georg Leistenschneider, Tomislav Majić, Simon Reiche et al.
3 citations
Abstract Classic psychedelics like LSD and psilocybin are showing promising effects in treating certain psychiatric disorders. Despite their low toxicity and lack of an addictive potential, in some individuals, psychedelics can be associated with persisting psychological harms. Hallucinogen Persisting Perception Disorder (HPPD) is one of those complications, a rare disorder characterized by...
The International journal on drug policy
April 1, 2022
Antonia Bendau, Leonard Viohl, Moritz Bruno Petzold et al.
The COVID-19 pandemic is presumably having an impact on the consumption of psychoactive substances. Social distancing and lockdown measures may particularly affect the use of "party drugs" (e.g., stimulants, dissociatives, and GHB/GBL) through the absence of typical use settings. We aimed to analyse the use patterns of those substances and underlying motivations before and during the pandemic....
Frontiers in Psychiatry
November 4, 2021
Ricarda Evens, Simon Reiche, Roman M. Marek et al.
16 citations
Introduction: The current corona virus disease (COVID-19) pandemic has caused a serious global health crisis that has affected large parts of the public and private life worldwide, including the use of psychoactive substances. In this study, we investigated the effect of the COVID-19 pandemic on the use of serotonergic psychedelics, i.e., the settings in which people use psychedelics, the...
Frontiers in Pharmacology
September 16, 2021
Lukas A Basedow, Thomas Riemer, Simon Reiche et al.
16 citations
Background: Serotonergic psychedelics (SPs) like LSD, psilocybin, DMT, and mescaline are a heterogeneous group of substances that share agonism at 5-HT 2a receptors. Besides the ability of these substances to facilitate profoundly altered states of consciousness, persisting psychological effects have been reported after single administrations, which outlast the acute psychedelic effects. In...
2021
Daan van der Gouwe, Tim Hirschfeld, Tomislav Majić et al.
Purpose of Review With the continuous emergence of new psychoactive substances, drug checking (DC) services are challenged by an increasingly complex drug market. Considering the resumed scientific and public interest in serotonergic psychedelics (SPs) like LSD, psilocybin, and 2C-B, we present the results of a literature search investigating the presence and proportion of SPs in DC samples....
Scientific Reports
December 9, 2020
Timo Torsten Schmidt, Simon Reiche, Caroline L. C. Hage et al.
12 citations
Kambô, the secretion of the Amazonian Giant Leaf Frog (Phyllomedusa bicolor) contains a plethora of bioactive peptides and was originally used by indigenous communities from the Amazon basin as medicine for improving hunting capacities. In the last 20 years, Kambô has spread to Western urban healing circles. To date it is still controversial whether the acute effects of Kambô include...
bioRxiv (Cold Spring Harbor Laboratory)
July 24, 2020
Timo Torsten Schmidt, Simon Reiche, Caroline L. C. Hage et al.
preprint
ABSTRACT Kambô is the name for the secretion of the Giant Leaf Frog (Phyllomedusa bicolor) containing a plethora of bioactive peptides. Originally, it is ritually used by different ethnicities from the Amazon basin as a remedy against bad luck in hunting. In the last twenty years, Kambô has spread to Western urban centers, often associated with the use of ayahuasca. Anecdotal reports claim...
Progress in neuro-psychopharmacology & biological psychiatry
February 2, 2018
Simon Reiche, Leo Hermle, Stefan Gutwinski et al.
125 citations
Anxiety and depression are some of the most common psychiatric symptoms of patients suffering with life-threatening diseases, often associated with a low quality of life and a poor overall prognosis. 5-HT2A-receptor agonists (serotonergic hallucinogens, 'psychedelics') like lysergic acid diethylamide (LSD) and psilocybin were first investigated as therapeutic agents in the 1960s. Recently,...